There is a greater interface between
herbal/traditional medicine and scientific medicine than most know about.
Medicine can be derived from many natural sources (e.g. Paclitaxel derived from
Pacific Yew tree) and medicinal chemists often focus on discovering new
therapeutic agents derived from nature. Tumeric, and more specifically the
extracted curcumin, has been of great interest lately due to curcumin’s anti-cancer
properties. Simply eating tumeric spice, however, does not yield a significant
anticancer effect for the majority of the body as curcumin has very poor absorption
across the intestine. However, properly formulated and purified curcumin, can
be a very powerful anticancer agent. It has an advantage over other chemotherapeutics
in that it has minimal side-effects. Recently, researchers at Yantie University
(China) used Maleimide-PEG-PLGA (PolyVivo AI020) and mPEG-PLGA (PolyVivo AK037)
from PolySciTech (www.polyscitech.com)
to generate curcumin loaded nanoparticles with Fab targeting ligands for
treating breast cancer. This research holds promise for effective breast-cancer
treatment with minimal chemotherapy side effects. Read more: Duan, Dongyu, Aiping Wang, Ling Ni, Liping
Zhang, Xiuju Yan, Ying Jiang, Hongjie Mu, Zimei Wu, Kaoxiang Sun, and Youxin
Li. "Trastuzumab-and Fab′ fragment-modified curcumin PEG-PLGA
nanoparticles: preparation and evaluation in vitro and in vivo."
International Journal of Nanomedicine 13 (2018): 1831. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868600/
“Abstract: Introduction: Nanoparticles (NPs) modified
with bio-ligands represent a promising strategy for active targeted drug
delivery to tumour. However, many targeted ligands, such as trastuzumab (TMAB),
have high molecular weight, limiting their application for targeting. In this
study, we prepared Fab’ (antigen-binding fragments cut from TMAB)-modified NPs
(Fab′-NPs) with curcumin (Cur) as a model drug for more effective targeting of
human epidermal growth factor receptor 2 (HER2/ErbB2/Neu), which is
overexpressed on breast cancer cells. Material and methods: The release
kinetics was conducted by dialysis bags. The ability to kill
HER2-overexpressing BT-474 cells of Fab′-Cur-NPs compared with TMAB-Cur-NPs was
conducted by cytotoxicity experiments. Qualitative and quantitative cell uptake
studies using coumarin-6 (fluorescent probe)-loaded NPs were performed by
fluorescence microscopy and flow cytometry. Pharmacokinetics and
biodistribution experiments in vivo were assessed by liquid
chromatography–tandem mass spectrometry (LC-MS/MS). Results: The release
kinetics showed that both Fab′-Cur-NPs and TMAB-Cur-NPs provided continuous,
slow release of curcumin for 72 h, with no significant difference. In vitro
cytotoxicity experiments showed that Fab′-Cur-NPs manifested prominent ability
to kill HER2-overexpressing BT-474 cells compared with TMAB-Cur-NPs.
Qualitative and quantitative cell uptake studies indicated that the
accumulation of Fab′-NPs was greater than that of TMAB-NPs in BT-474 (HER2+)
cells; However, there was no significant difference in MDA-MB-231 (HER2−)
cells. Pharmacokinetics and biodistribution experiments in vivo demonstrated
that the half-life (t1/2) and area under the blood concentration-time curve
(AUC0-t) of Fab′-Cur-NPs increased 5.30-fold and 1.76-fold relative to those of
TMAB-Cur-NPs, respectively. Furthermore, the tumor accumulation of Fab′-Cur-NPs
was higher than that of TMAB-Cur-NPs. Conclusion: Fab′ fragment has greater
capacity than the intact antibody to achieve tumor targeting through NP-based
delivery. Keywords: trastuzumab-modified curcumin nanoparticles, Fab′-modified
curcumin nanoparticles, pharmacokinetics, biodistribution, tumour targeting,
breast cancer”
BPCR conference (August 29, 2018 9AM - 4PM: Kurz Purdue Technology Center,
West Lafayette, IN) is a free, 1-day scientific networking conference hosted by
Akina, Inc. which focuses on research companies in the biotechnology,
pharmaceutical, medical, and broader life-science fields. See more at BPCRconference.com
No comments:
Post a Comment